Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Venetoclax in Fit Newly Diagnosed AML
NCT05471700Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of venetoclax in acute myeloid leukemia (AML), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Overall Response Rate at 36 months. Started Sep 2022; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05471700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471700.